Prospective study of immunomodulation with GM-CSF, IL-2, and rituximab following autologous stem cell transplant (SCT) in patients with relapsed lymphomas.

被引：0
|
作者：
Smith, SM
Grinblatt, DL
Gajewski, T
Harlin, H
Welborne, K
Conner, K
Larson, RA
Rich, E
Odenike, O
Zimmerman, T
van Besien, K
机构：
[1] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[2] Northwestern Univ, Evanston, IL USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.918.918
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
918
引用
收藏
页码：263A / 263A
页数：1
相关论文
共 50 条
  • [31] Phase II study of thalidomide, interleukin-2 (IL-2), and granulocyte macrophagecolony stimulating factor (GM-CSF) in patients (pts) with metastatic renal cell carcinoma (MRCC).
    Morgan, M
    Rawat, A
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 432S - 432S
  • [32] Phase I trial of interleukin-2 (IL-2) and rituximab in patients (pts) with relapsed or refractory B-cell lymphomas (R/R-BCL).
    Porcu, P
    Farag, S
    Marcucci, G
    Avalos, B
    Rhoades, C
    Fisher, B
    Byrd, JC
    Grever, MR
    Caligiuri, MA
    BLOOD, 2001, 98 (11) : 245B - 245B
  • [33] A randomized prospective study of peripheral blood stem cell (PBSC) mobilization with cyclophosphamide (CTX) in combination with G-CSF, GM-CSF, or sequential GM-CSF followed by G-CSF, in non-Hodgkin's lymphoma (NHL) patients.
    Gazitt, Y
    Callander, N
    Freytes, CO
    Shaughnessy, P
    Tsai, TW
    Alsina, M
    Anderson, JE
    Devore, P
    BLOOD, 1999, 94 (10) : 338B - 338B
  • [34] Phase II Study of thalidomide, Interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC).
    Rawat, A
    Arnato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 431S - 431S
  • [35] IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2) FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN'S LYMPHOMA
    Holmberg, L. A.
    Maloney, D. G.
    Bensinger, W., I
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 39 - 39
  • [36] Effect of posttransplant+7 day GM-CSF usage on hematological recovery time in autologous peripheral blood stem cell transplantation (PBSCT): a Prospective randomized study
    Kuzhan, O
    Arpaci, F
    Ozturk, B
    Ozet, A
    Komurcu, S
    Turan, M
    Beyzadeoglu, M
    Sengul, A
    Yalcin, A
    BONE MARROW TRANSPLANTATION, 2001, 27 : S164 - S164
  • [37] Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-cell non-Hodgkin's lymphomas (NHL): The impact of histologies of follicular (FL) origin.
    Khouri, IF
    Saliba, RM
    Acholonu, S
    Okoroji, GJ
    Hosing, C
    Fayad, L
    Couriel, DR
    Pro, B
    Giralt, S
    Andersson, B
    Younes, A
    McLaughlin, P
    Champlin, RE
    BLOOD, 2003, 102 (11) : 735A - 736A
  • [38] Diagnostic performance of GM-CSF and IL-2 in response to long-term specific-antigen cell stimulation in patients with active and latent tuberculosis infection
    Elvira Balcells, Maria
    Ruiz-Tagle, Cinthya
    Tiznado, Camila
    Garcia, Patricia
    Naves, Rodrigo
    TUBERCULOSIS, 2018, 112 : 110 - 119
  • [39] Phase II study of thalidomide, interleukin-2 (IL-2) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (MRCC).
    Amato, R
    Rawat, A
    Attumi, T
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8977S - 8977S
  • [40] A pilot study of cyclophosphamide, carboplatin, etoposide (CCE), and G-CSF with or without rituximab for cytoreduction and peripheral blood stem cell mobilization in patients with relapsed or refractory lymphomas
    Stevenson, DE
    Haroff, AL
    Ririe, DW
    Splichal, JE
    Ornstein, DL
    Heller, BJ
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 121 - 121
12345